Home/Sumitomo Pharma/Akihiro Kobayashi
AK

Akihiro Kobayashi

Executive Officer, Head of R&D Division

Sumitomo Pharma

Sumitomo Pharma Pipeline

DrugIndicationPhase
LATUDA® (lurasidone HCl)Major Depressive Disorder (adjunctive)Launched / Phase 3
SP-3164Non-Hodgkin's LymphomaPhase 1/2
DSP-0390Recurrent High-Grade GliomaPhase 1/2
SP-2577 (Seclidemstat)Sarcomas & Solid TumorsPhase 1/2
Rexlemestrocel-LChronic Low Back PainPhase 3
Ansofaxine (TP1)Major Depressive DisorderFiled (US)